Erythroid lineage-restricted expression of Jak2V617F is sufficient to induce a myeloproliferative disease in mice

Haematologica

Volumn 97, Issue 9, 2012, Pages 1389-1393

  Akada, Hajime ^a   Akada, Saeko ^a   Hutchison, Robert E ^a   Mohi, Golam ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Erythroid progenitors; Jak2V617F; MPNs

Indexed keywords

CD11B ANTIGEN; CD61 ANTIGEN; CD71 ANTIGEN; ERYTHROPOIETIN; FIBRINOGEN RECEPTOR; HEMOGLOBIN; CRE RECOMBINASE; ERYTHROPOIETIN RECEPTOR; INTEGRASE; JAK2 PROTEIN, MOUSE; JANUS KINASE 2;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL TRANSPLANTATION; CLONOGENIC ASSAY; CONTROLLED STUDY; ERYTHROCYTE COUNT; ERYTHROID PRECURSOR CELL; FLOW CYTOMETRY; GENE; GENE EXPRESSION; HEMATOCRIT; JAK2V617F GENE; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; POLYCYTHEMIA; SPLEEN WEIGHT; SPLENOMEGALY; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL LINEAGE; COMPARATIVE STUDY; COMPLICATION; FEMALE; GENETICS; HEMATOPOIETIC STEM CELL; HUMAN; METABOLISM; MUTATION; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; CELL LINEAGE; CELLS, CULTURED; ERYTHROID PRECURSOR CELLS; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; HUMANS; INTEGRASES; JANUS KINASE 2; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA; RECEPTORS, ERYTHROPOIETIN; SIGNAL TRANSDUCTION;

EID: 84865849280     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.059113     Document Type: Article

References (24)

1. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature. 2005;434(7037):1144-8.
2. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-97.
3. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-61.
4. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Eng J Med. 2005;352 (17):1779-90.
5. Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, et al. Identification of an Acquired JAK2 Mutation in Polycythemia Vera. J Biol Chem. 2005;280(24):22788-92.
6. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006;107(11):4274-81.
7. Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008;111(8):3931-40.
8. Xing S, Wanting TH, Zhao W, Ma J, Wang S, Xu X, et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood. 2008;111(10):5109-17.
9. Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood. 2010;115(17):3589-97.
10. Marty C, Lacout C, Martin A, Hasan S, Jacquot S, Birling MC, et al. Myelo-proliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood. 2010;116(5):783-7.
11. Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F, et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell. 2010;17(6): 584-96.
12. Li J, Spensberger D, Ahn JS, Anand S, Beer PA, Ghevaert C, et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood. 2010;116(9):1528-38.
13. Jamieson CH, Gotlib J, Durocher JA, Chao MP, Mariappan MR, Lay M, et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci USA. 2006;103(16):6224-9.
14. Dupont S, Massé A, James C, Teyssandier I, Lécluse Y, Larbret F, et al. The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood. 2007;110(3):1013-21.
15. Geron I, Abrahamsson AE, Barroga CF, Kavalerchik E, Gotlib J, Hood JD, et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell. 2008;13(4):321-30.
16. Heinrich AC, Pelanda R, Klingmüller U. A mouse model for visualization and conditional mutations in the erythroid lineage. Blood. 2004;104(3):659-66.
17. Kühn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science 1995;269(5229):1427-9.
18. Singbrant S, Russell MR, Jovic T, Liddicoat B, Izon DJ, Purton LE, et al. Erythropoietin couples erythropoiesis, B-lymphopoiesis, and bone homeostasis within the bone marrow microenvironment. Blood. 2011; 117(21):5631-42.
19. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367(6464):645-8.
20. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730-7.
21. Huntly BJ, Shigematsu H, Deguchi K, Lee BH, Mizuno S, Duclos N, et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell. 2004;6(6):587-96.
22. Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006;442(7104):818-22.
23. Guibal FC, Alberich-Jorda M, Hirai H, Ebralidze A, Levantini E, Di Ruscio A, et al. Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia. Blood. 2009;114 (27):5415-25.
24. Waterstrat A, Liang Y, Swiderski CF, Shelton BJ, Van Zant G. Congenic interval of CD45/Ly-5 congenic mice contains multiple genes that may influence hematopoietic stem cell engraftment. Blood. 2010;115(2): 408-17.